Loading…

Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction

Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the respo...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2010, Vol.159 (1), p.55-62
Main Authors: Harkness, James R., MD, Sabatine, Marc S., MD, MPH, Braunwald, Eugene, MD, Morrow, David A., MD, MPH, Sloan, Sarah, MS, Wiviott, Stephen D., MD, Giugliano, Robert P., MD, SM, Antman, Elliott M., MD, Cannon, Christopher P., MD, Scirica, Benjamin M., MD, MPH
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723
cites cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723
container_end_page 62
container_issue 1
container_start_page 55
container_title The American heart journal
container_volume 159
creator Harkness, James R., MD
Sabatine, Marc S., MD, MPH
Braunwald, Eugene, MD
Morrow, David A., MD, MPH
Sloan, Sarah, MS
Wiviott, Stephen D., MD
Giugliano, Robert P., MD, SM
Antman, Elliott M., MD
Cannon, Christopher P., MD
Scirica, Benjamin M., MD, MPH
description Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (>70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P < .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P < .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P < .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P < .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.
doi_str_mv 10.1016/j.ahj.2009.10.033
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733622282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000287030900831X</els_id><sourcerecordid>3238257731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</originalsourceid><addsrcrecordid>eNp9ks1u1DAQxy0EotvCA3BBlhDqKcvYTpyskCqhqnxIlTi0SNwsxxmD0yQutrNiX4WnxWG3FPXAyZ7xb8Yz8x9CXjBYM2DyTb_W3_s1B9hkew1CPCIrBpu6kHVZPiYrAOBFU4M4Iscx9tmUvJFPyREHBvlWr8ivi58Jp0S9pVfXRcRv42IFjH6Yk_MT1TZhoNa1wU1-2EUXqe66SN14G_wWOxpcvKExBZ2cdUb_CUqemsFN2RwO78YHpNaHf3_BAbd7ftx5o0PnMu4mq4NZvM_IE6uHiM8P5wn58v7i-vxjcfn5w6fzd5eFKWWVCik7wUBjUzUtNK3ecOCtNKztqrplhgnWINcCWsFNU7eWc4bMaGM2FYOy5uKEnO7z5oZ-zBiTGl00OAx6Qj9HVQshOefNQr56QPZ-DlMuTrEKSsmYqMtMsT1lgo8xoFW3wY067BQDteimepV1U4tuiyvrlmNeHjLP7Yjd34g7oTLw-gDomKdqg56Mi_ccF1DyimXu7Z7DPLGtw6CicTgZ7FxAk1Tn3X_LOHsQfSfjDe4w3nerIlegrpYFW_YLNgCNYF_Fb769zJU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504611374</pqid></control><display><type>article</type><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><source>ScienceDirect Journals</source><creator>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</creator><creatorcontrib>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</creatorcontrib><description>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (&gt;70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P &lt; .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P &lt; .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P &lt; .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P &lt; .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2009.10.033</identifier><identifier>PMID: 20102867</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adult ; Aged ; Angina pectoris ; Aspirin ; Biological and medical sciences ; Blood pressure ; Cardiology. Vascular system ; Cardiovascular ; Clinical outcomes ; Confidence Intervals ; Coronary Angiography ; Coronary Circulation - drug effects ; Coronary Circulation - physiology ; Coronary heart disease ; Diabetes ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Electrocardiography ; Female ; Fibrinolysis - drug effects ; Follow-Up Studies ; Heart ; Heart attacks ; Heart failure ; Humans ; Hypertension ; Male ; Medical imaging ; Medical sciences ; Middle Aged ; Mortality ; Myocardial Infarction - diagnosis ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocarditis. Cardiomyopathies ; Odds Ratio ; Platelet Aggregation Inhibitors - administration &amp; dosage ; Probability ; Risk Assessment ; Severity of Illness Index ; Survival Analysis ; Thrombolytic Therapy - methods ; Ticlopidine - administration &amp; dosage ; Ticlopidine - analogs &amp; derivatives ; Time Factors ; Treatment Outcome ; Vascular Patency - drug effects ; Veins &amp; arteries</subject><ispartof>The American heart journal, 2010, Vol.159 (1), p.55-62</ispartof><rights>Mosby, Inc.</rights><rights>2010 Mosby, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</citedby><cites>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22304251$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20102867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harkness, James R., MD</creatorcontrib><creatorcontrib>Sabatine, Marc S., MD, MPH</creatorcontrib><creatorcontrib>Braunwald, Eugene, MD</creatorcontrib><creatorcontrib>Morrow, David A., MD, MPH</creatorcontrib><creatorcontrib>Sloan, Sarah, MS</creatorcontrib><creatorcontrib>Wiviott, Stephen D., MD</creatorcontrib><creatorcontrib>Giugliano, Robert P., MD, SM</creatorcontrib><creatorcontrib>Antman, Elliott M., MD</creatorcontrib><creatorcontrib>Cannon, Christopher P., MD</creatorcontrib><creatorcontrib>Scirica, Benjamin M., MD, MPH</creatorcontrib><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (&gt;70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P &lt; .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P &lt; .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P &lt; .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P &lt; .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</description><subject>Adult</subject><subject>Aged</subject><subject>Angina pectoris</subject><subject>Aspirin</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Clinical outcomes</subject><subject>Confidence Intervals</subject><subject>Coronary Angiography</subject><subject>Coronary Circulation - drug effects</subject><subject>Coronary Circulation - physiology</subject><subject>Coronary heart disease</subject><subject>Diabetes</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Fibrinolysis - drug effects</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Odds Ratio</subject><subject>Platelet Aggregation Inhibitors - administration &amp; dosage</subject><subject>Probability</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Thrombolytic Therapy - methods</subject><subject>Ticlopidine - administration &amp; dosage</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vascular Patency - drug effects</subject><subject>Veins &amp; arteries</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9ks1u1DAQxy0EotvCA3BBlhDqKcvYTpyskCqhqnxIlTi0SNwsxxmD0yQutrNiX4WnxWG3FPXAyZ7xb8Yz8x9CXjBYM2DyTb_W3_s1B9hkew1CPCIrBpu6kHVZPiYrAOBFU4M4Iscx9tmUvJFPyREHBvlWr8ivi58Jp0S9pVfXRcRv42IFjH6Yk_MT1TZhoNa1wU1-2EUXqe66SN14G_wWOxpcvKExBZ2cdUb_CUqemsFN2RwO78YHpNaHf3_BAbd7ftx5o0PnMu4mq4NZvM_IE6uHiM8P5wn58v7i-vxjcfn5w6fzd5eFKWWVCik7wUBjUzUtNK3ecOCtNKztqrplhgnWINcCWsFNU7eWc4bMaGM2FYOy5uKEnO7z5oZ-zBiTGl00OAx6Qj9HVQshOefNQr56QPZ-DlMuTrEKSsmYqMtMsT1lgo8xoFW3wY067BQDteimepV1U4tuiyvrlmNeHjLP7Yjd34g7oTLw-gDomKdqg56Mi_ccF1DyimXu7Z7DPLGtw6CicTgZ7FxAk1Tn3X_LOHsQfSfjDe4w3nerIlegrpYFW_YLNgCNYF_Fb769zJU</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Harkness, James R., MD</creator><creator>Sabatine, Marc S., MD, MPH</creator><creator>Braunwald, Eugene, MD</creator><creator>Morrow, David A., MD, MPH</creator><creator>Sloan, Sarah, MS</creator><creator>Wiviott, Stephen D., MD</creator><creator>Giugliano, Robert P., MD, SM</creator><creator>Antman, Elliott M., MD</creator><creator>Cannon, Christopher P., MD</creator><creator>Scirica, Benjamin M., MD, MPH</creator><general>Mosby, Inc</general><general>Mosby</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><author>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angina pectoris</topic><topic>Aspirin</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Clinical outcomes</topic><topic>Confidence Intervals</topic><topic>Coronary Angiography</topic><topic>Coronary Circulation - drug effects</topic><topic>Coronary Circulation - physiology</topic><topic>Coronary heart disease</topic><topic>Diabetes</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Fibrinolysis - drug effects</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Odds Ratio</topic><topic>Platelet Aggregation Inhibitors - administration &amp; dosage</topic><topic>Probability</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Thrombolytic Therapy - methods</topic><topic>Ticlopidine - administration &amp; dosage</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vascular Patency - drug effects</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harkness, James R., MD</creatorcontrib><creatorcontrib>Sabatine, Marc S., MD, MPH</creatorcontrib><creatorcontrib>Braunwald, Eugene, MD</creatorcontrib><creatorcontrib>Morrow, David A., MD, MPH</creatorcontrib><creatorcontrib>Sloan, Sarah, MS</creatorcontrib><creatorcontrib>Wiviott, Stephen D., MD</creatorcontrib><creatorcontrib>Giugliano, Robert P., MD, SM</creatorcontrib><creatorcontrib>Antman, Elliott M., MD</creatorcontrib><creatorcontrib>Cannon, Christopher P., MD</creatorcontrib><creatorcontrib>Scirica, Benjamin M., MD, MPH</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harkness, James R., MD</au><au>Sabatine, Marc S., MD, MPH</au><au>Braunwald, Eugene, MD</au><au>Morrow, David A., MD, MPH</au><au>Sloan, Sarah, MS</au><au>Wiviott, Stephen D., MD</au><au>Giugliano, Robert P., MD, SM</au><au>Antman, Elliott M., MD</au><au>Cannon, Christopher P., MD</au><au>Scirica, Benjamin M., MD, MPH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2010</date><risdate>2010</risdate><volume>159</volume><issue>1</issue><spage>55</spage><epage>62</epage><pages>55-62</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (&gt;70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P &lt; .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P &lt; .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P &lt; .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P &lt; .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>20102867</pmid><doi>10.1016/j.ahj.2009.10.033</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-8703
ispartof The American heart journal, 2010, Vol.159 (1), p.55-62
issn 0002-8703
1097-6744
language eng
recordid cdi_proquest_miscellaneous_733622282
source ScienceDirect Journals
subjects Adult
Aged
Angina pectoris
Aspirin
Biological and medical sciences
Blood pressure
Cardiology. Vascular system
Cardiovascular
Clinical outcomes
Confidence Intervals
Coronary Angiography
Coronary Circulation - drug effects
Coronary Circulation - physiology
Coronary heart disease
Diabetes
Dose-Response Relationship, Drug
Drug Administration Schedule
Electrocardiography
Female
Fibrinolysis - drug effects
Follow-Up Studies
Heart
Heart attacks
Heart failure
Humans
Hypertension
Male
Medical imaging
Medical sciences
Middle Aged
Mortality
Myocardial Infarction - diagnosis
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Myocarditis. Cardiomyopathies
Odds Ratio
Platelet Aggregation Inhibitors - administration & dosage
Probability
Risk Assessment
Severity of Illness Index
Survival Analysis
Thrombolytic Therapy - methods
Ticlopidine - administration & dosage
Ticlopidine - analogs & derivatives
Time Factors
Treatment Outcome
Vascular Patency - drug effects
Veins & arteries
title Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A26%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extent%20of%20ST-segment%20resolution%20after%20fibrinolysis%20adds%20improved%20risk%20stratification%20to%20clinical%20risk%20score%20for%20ST-segment%20elevation%20myocardial%20infarction&rft.jtitle=The%20American%20heart%20journal&rft.au=Harkness,%20James%20R.,%20MD&rft.date=2010&rft.volume=159&rft.issue=1&rft.spage=55&rft.epage=62&rft.pages=55-62&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2009.10.033&rft_dat=%3Cproquest_cross%3E3238257731%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504611374&rft_id=info:pmid/20102867&rfr_iscdi=true